Area of focus

Medical Devices

Creating and commercializing a cutting-edge medical device is demanding work. Remaining compliant in the face of ever increasing regulation makes that job even more difficult.

We leverage the vast experience gleaned from guiding companies of all sizes through the hard-to-navigate health care environment. We ask the right questions and explore uncovered possibilities to put your product in the best position for success.

Representative experience

Obtaining the FDA’s designation of expedited review status for a novel orthopedic and women’s health device and negotiated favorable review timetables.

Managing PMA and Advisory Panel Process and helped secure approval for novel, noninvasive screening test using advanced DNA technology to detect colorectal cancer.

Drafting one of the first de novo submissions and obtaining multiple downclassifications and subsequent premarket clearances for capsule endoscopy imaging systems.

Assisting a client seeking FDA regulatory marketing approval of the first ever Retinal Prosthesis System intended for partial restoration of vision.

Conducting due diligence for investment bank on medical device startup, uncovering several important FDA issues that substantially altered the target’s valuation.

Assisting a client that manufactures an artificial heart to reverse Medicare’s national noncoverage decision and secure more advantageous Medicare reimbursements.

Advising a U.S.-based national trade association that provides educational assistance to medical technology companies in Chinese medical device reimbursement rules and policies.

Acting for a global medical device manufacturer on various claims regarding cardiac devices.

Advising a U.S. medical devices company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Coordinating the defense of a manufacturer of implantable class III medical devices against alleged liability in clinical trials after a voluntary worldwide product withdrawal.

Assisting a medical device manufacturer with investigations by the authorities, criminal investigations, and civil proceedings arising out of the over-exposure of patients to radiations.

Representing a leading medical device manufacturer in a global recall of one of its products in more than 70 countries.

Counsel to a publicly traded company in a voluntary disclosure to USDOJ and the SEC regarding alleged payments to win public tenders and in follow-on litigation.

Represented a global technology company in the creation of a joint venture to develop next-generation surgical robots.

We have prepared more companies for panel meetings in the last two years than almost any other law firm or consultant in the country.


Modifications to 510(k) - Cleared devices: Assessing the impact of FDA's 2017 final guidance documents

On December 6, Danielle Humphrey and Kristin Zielinski Duggan led a complimentary webinar, which covered:

Quick view Full view

Sponsorships and Speaking Engagements

FDLI Introduction to Medical Device Law and Regulation

On November 7, 2018 Danielle Humphrey presented a session titled "Clinical Investigations: Investigational Device Exemption (IDE), Institutional Review Boards (IRBs), and Informed Consent"...

Quick view Full view

Sponsorships and Speaking Engagements

9th Annual Advertising and Promotion of Medical Devices Conference

On November 6, 2018, Danielle Humphrey presented a session on Medical Device Enforcement and Compliance at the AdvaMed Advertising and Promotion of Medical Devices Conference.

Quick view Full view

Sponsorships and Speaking Engagements

Master Class: Medical Device Clinical Research: The Path From Concept to Approval (Part 2)

Lina Kontos spoke in the Master Class: Medical Device Clinical Research: The Path From Concept to Approval (Part 2) session at the Magi's Clinical Research Conference - 2018 West on Sunday, ...

Quick view Full view

Hogan Lovells Publications

Crackdown coming? Draft guidance suggests FDA is looking more closely at clinical trial disclosures Pharmaceuticals and Biotechnology Alert

On Friday, September 21, the Food and Drug Administration (FDA) published a draft guidance titled "Civil Money Penalties Relating to the Data Bank."

Quick view Full view
Loading data